Agilent provides xCELLigence impedance-based, label-free, real time cell analysis system and NovoCyte flow cytometers.
Automated microscopy and Spatial Proteomics
Real-time, label free cell analysis
Nano and micro particle analysis
Accelerate to discover
Back to filter
Show all topics (10)
Related topics
Theranostics: From Mice to Men and Back
Jun 25, 2024
Recorded webinar
Presenters: Prof. Dr. Ken Herrmann and Prof. Dr. Katharina Lückerath – Moderator: Hannah Notebaert
Orion 2024 AACR poster: 17-plex single-step stain and imaging of cell Lung Carcinoma
Jun 21, 2024
RareCyte Orion is a benchtop, high resolution, whole slide multimodal imaging instrument. A combination of quantitative...
Hypoxia in the Tumor Immune Microenvironment (TIME)
Jun 6, 2024
Thursday, 11 July 2024, 16:00 CET | 10:00 EST
Zaver M. Bhujwalla, PhD
X-RAD 320 for irradiation therapy during quantifying study for in vivo collagen reorganization
Jun 5, 2024
Quantifying in vivo collagen reorganization during immunotherapy in murine melanoma with second harmonic generation...
Use of MRI and microCT to evaluate gene therapy for the treatment of discogenic back pain
Jun 4, 2024
MRI images were obtained using the 9.4T Bruker BioSpec system, equipped with 40 mm 1H quadrature volume resonator, and...
Exosome-Mediated Delivery of Small Molecules, RNA & DNA for Development of Novel Cancer Therapeutics
Jun 3, 2024
Disha Moholkar of University of Louisville's Gupta Lab
Tuesday, June 11, 2024, 6:30 PM...
Emulate in vivo conditions – introduce shear flow to your experiments with BioFlux system
May 27, 2024
Most research is still conducted in vitro without the presence of flow. We use the BioFlux System to give you the...
High-frequency Ultrasound System For Preclinical Imaging
May 13, 2024
The Prospect T1 is an innovative high-frequency ultrasound system designed specifically for in vivo preclinical imaging...
Differentation displacement in acute myeloid leukemia through enhancer activation
Aug 7, 2018
LSD1 is a flavin adenine dinucleotide (FAD)-dependent homolog of the amine oxidase family and there was recently brought attention to it as a potential therapeutic target. The interest came from an observation of unusually high expression of LSD1 in certain types of poor-prognosis cancers. It was previously thought that LSD1 removes monomethyl and dymethyl histone marks. However, recently it was showed that it interacts with multiple transcripton factor. This raised a possibility of other drugs being used.
New inhibitor ORY-1001 was succesfully tested on LSD1 and blast cell differentioation was observed. The flow cytometric testing on this experiment was done with Novocyte. ORY-1001 disrupts the protein interaction between LSD1 and GFI1.
Related technologies: Conventional flow cytometry
Get more info
Brand profile
